Medical Condition News

RSS

Novel biomarker test accurately detects proteins secreted from asbestos-related tumors

Researchers investigating a novel biomarker test believe it is the most accurate yet in detecting proteins secreted from tumors caused by exposure to asbestos. Study results of this aptamer proteomic technology were presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

4 Apr 2011

Study reveals increased incidence of major adverse cardiac events in patients with severe psoriasis

Psoriasis is a common inflammatory skin disease, and if severe, has been demonstrated to be a risk factor for cardiovascular (CV) disease. However, the degree to which psoriasis is associated with major adverse cardiac events (MACE), such as heart attack, stroke, and cardiovascular death has not been defined. Now, new research from the University of Pennsylvania School of Medicine has revealed an increased incidence of MACE in patients with severe psoriasis.

4 Apr 2011

Coronary computed tomographic angiography to evaluate acute chest pain reduces hospital admissions

Hospital admissions at Stony Brook University Medical Center on Long Island were significantly reduced when using coronary computed tomographic angiography (CCTA) to evaluate patients presenting in the emergency department (ED) with acute chest pain (ACP), according to research results presented during a scientific session at the American College of Cardiology's 60th Annual Scientific Session and Expo in New Orleans on April 3.

4 Apr 2011

Pronto to distribute Signal's Myeloma Prognostic Risk Signature test in Israel

Signal Genetics, the parent company of Myeloma Health LLC, and Pronto Diagnostics Ltd, both of which are privately held predictive genetic testing companies focused on oncology, announced that they have entered into a Distribution Agreement whereby Pronto will be the exclusive representative and distributor for Signal's Myeloma Prognostic Risk Signature (MyPRS) test in Israel.

4 Apr 2011

FDA approves St. Jude Medical's Safire BLU and Therapy Cool Path irrigated ablation catheters

St. Jude Medical, Inc., a global medical device company, announced today that it has received U.S. Food and Drug Administration (FDA) approval of two new irrigated ablation catheters - the Safire BLU™ Bi-directional Irrigated Ablation Catheter and the Therapy™ Cool Path™ bi-directional ablation catheter.

4 Apr 2011

Pfizer receives FDA Refusal to File letter for tafamidis to treat Transthyretin Familial Amyloid Polyneuropathy

Pfizer Inc. announced today that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) for tafamidis, the company's novel, oral investigational compound for patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP).

4 Apr 2011

FDA grants 510(k) clearance for superDimension's marker delivery kit

superDimension, Ltd., a privately-owned company that develops minimally invasive interventional pulmonology devices, today announced it has received FDA 510(k) clearance for the superDimension marker delivery kit. The kit is designed for use with the Company's Electromagnetic Navigational Bronchoscopy (ENB) system, which has treated a total of 20,000 total patients since commercial launch.

4 Apr 2011

Orexo partner ProStrakan launches Abstral in the US

Orexo AB announces today that its partner ProStrakan Group plc has launched Abstral in the United States.

4 Apr 2011

Mylan receives FDA approval for generic Xalatan Ophthalmic Solution

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Latanoprost Ophthalmic Solution, 0.005%, the generic version of Pharmacia and Upjohn's Xalatan® Ophthalmic Solution, an eyedrop that lowers pressure in the eye.

4 Apr 2011

People with lung cancer more likely to have high-risk forms of HPV antibodies

Researchers with the International Agency for Research on Cancer (IARC) have found that people with lung cancer were significantly more likely to have several high-risk forms of human papillomavirus (HPV) antibodies compared to those who did not have lung cancer. These results, which were presented at the AACR 102nd Annual Meeting 2011, held April 2-6, indicate that HPV antibodies are substantially increased in people with lung cancer.

4 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011

Aspirin usage associated with decrease in pancreatic cancer risk

The use of aspirin at least once per month is associated with a significant decrease in pancreatic cancer risk, according to results of a large case-control study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

4 Apr 2011

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload technology, today disclosed the profile and first preclinical data for the Company's novel IMGN529 product candidate for the treatment of B-cell malignancies including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

4 Apr 2011

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Oncothyreon Inc. today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase, at the American Association of Cancer Research meeting in Orlando, Florida.

4 Apr 2011

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.

4 Apr 2011

AngioDynamics introduces DuraMax chronic dialysis catheter in the U.S.

AngioDynamics announced today the U.S. launch and initial shipments of the next generation DuraMax stepped-tip chronic dialysis catheter and the DuraMaxVP kit.

4 Apr 2011

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies, announced today the results of a healthy volunteers Phase I clinical study of Bendavia™, a novel compound that targets the mitochondrion to treat ischemia reperfusion injury.

4 Apr 2011

New anti-angiogenic therapy can lead to tumour growth inhibition

Scientists from the School of Pharmacy at Queen's University Belfast and Almac Discovery Ltd, announce the first publication describing a potential new anti-angiogenic therapy based on a natural protein first discovered at QUB. Anti-angiogenics prevent the growth of new blood vessels in tumours and starve them of nutrients, leading to inhibition of tumour growth.

4 Apr 2011

Abiomed presents Impella PROTECT II study final results in PCI at ACC and i2 Summit

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today announced the final results from the PROTECT II study, presented by William O'Neill, M.D., Dean of University of Miami and Principal Investigator of PROTECT II, at the American College of Cardiology's 60th Annual Scientific Session and i2 Summit 2011 in New Orleans.

4 Apr 2011

Oral cancer more common among Americans with HPV16 viral infections

A serious change in the cause of oral cancer is taking place nationally, and its implications are impacting the American public in a manner that a decade ago no one would have predicted.

4 Apr 2011

Medical Condition News

Novel biomarker test accurately detects proteins secreted from asbestos-related tumors

Study reveals increased incidence of major adverse cardiac events in patients with severe psoriasis

Coronary computed tomographic angiography to evaluate acute chest pain reduces hospital admissions

Pronto to distribute Signal's Myeloma Prognostic Risk Signature test in Israel

FDA approves St. Jude Medical's Safire BLU and Therapy Cool Path irrigated ablation catheters

Pfizer receives FDA Refusal to File letter for tafamidis to treat Transthyretin Familial Amyloid Polyneuropathy

FDA grants 510(k) clearance for superDimension's marker delivery kit

Orexo partner ProStrakan launches Abstral in the US

Mylan receives FDA approval for generic Xalatan Ophthalmic Solution

People with lung cancer more likely to have high-risk forms of HPV antibodies

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Aspirin usage associated with decrease in pancreatic cancer risk

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

AngioDynamics introduces DuraMax chronic dialysis catheter in the U.S.

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

New anti-angiogenic therapy can lead to tumour growth inhibition

Abiomed presents Impella PROTECT II study final results in PCI at ACC and i2 Summit

Oral cancer more common among Americans with HPV16 viral infections

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News